Özet
Translocation type renal cell carcinomas (t-RCCs) are newly defined renal tubular epithelial tumors. The oncogenic activations of TFE3 and TFEB genes, which are two members of the microphthalmia-associa-transcription factor (MiTF) family, due to translocations and fusions with different partner genes plays a role in their pathogenesis. The clinical and pathological spectrum of these tumors, which are many times misdiagnosed because of the lack of knowledge regarding them, have not yet been fully demonstrated.
In this study, 89 cases with the potential for t-RCC were identified among all renal cell carcinomas diagnosed in the Hacettepe University Medical School Department of Pathology between 2000 and 2018. In the fluorescence in-situ hybridization study, 32 were diagnosed as TFE3 and 3 were diagnosed as TFEB t-RCC. These thirty-five cases were analyzed and clinical, histomorphological and immunohistochemical features were determined. The clinical course of these tumors were documented and the relationship between their prognosis and morphological features was attempted to be determined. Thus, some of the histological findings show statistically significant correlation with general and disease-free survival. The different morphological features that are of prognostic significance are likely to be associated with different fusion gene partners. In our study, we aimed to analyze the genetic changes of tumors in a more detailed way and to use advanced molecular methods. However, the RT-PCR method used did not yield a result in formalin-fixed paraffin-embedded tumor samples.
Künye
1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. The Lancet.373(9669):1119-32.
2. Zhuge Y, Cheung MC, Yang R, Perez EA, Koniaris LG, Sola JE. Pediatric non-Wilms renal tumors: subtypes, survival, and prognostic indicators. J Surg Res. 2010;163(2):257-63.
3. Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z, Montironi R. 2009 update on the classification of renal epithelial tumors in adults. International journal of urology : official journal of the Japanese Urological Association. 2009;16(5):432-43.
4. Ross H, Argani P. Xp11 translocation renal cell carcinoma. Pathology. 2010;42(4):369-73.
5. Bruder E, Passera O, Harms D, Leuschner I, Ladanyi M, Argani P, et al. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol. 2004;28(9):1117-32.
6. Komai Y, Fujiwara M, Fujii Y, Mukai H, Yonese J, Kawakami S, et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res. 2009;15(4):1170-6.
7. Classe M, Malouf GG, Su X, Yao H, Thompson EJ, Doss DJ, et al. Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas. Histopathology. 2017;70(7):1089-97.
8. Martignoni G, Pea M, Gobbo S, Brunelli M, Bonetti F, Segala D, et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2009;22(8):1016-22.
9. Argani P, Ladanyi M. Translocation Carcinomas of the Kidney. Clinics in Laboratory Medicine.25(2):363-78.
10. Just PA, Letourneur F, Pouliquen C, Dome F, Audebourg A, Biquet P, et al. Identification by FFPE RNA-Seq of a new recurrent inversion leading to RBM10-TFE3 fusion in renal cell carcinoma with subtle TFE3 break-apart FISH pattern. Genes Chromosomes Cancer. 2016;55(6):541-8.
11. Argani P, Zhong M, Reuter VE, Fallon JT, Epstein JI, Netto GJ, et al. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. Am J Surg Pathol. 2016;40(6):723-37.
12. de Jong B, Molenaar IM, Leeuw JA, Idenberg VJ, Oosterhuis JW. Cytogenetics of a renal adenocarcinoma in a 2-year-old child. Cancer Genet Cytogenet. 1986;21(2):165-9.
13. Eble JL, Sauter G, Epstein JI. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs WHO Classification of Tumours, Volume 7: World Health Organization; 2004.
14. Argani P, Hawkins A, Griffin CA, Goldstein JD, Haas M, Beckwith JB, et al. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol. 2001;158(6):2089-96.
15. Moch H, International Agency for Research on C, Organización Mundial de la S. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC); 2016.
16. Database G-HG. TFE3 Gene - Genecards [Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=TFE3.
17. Database G-HG. TFEB Gene - Genecards [Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=TFEB.
18. Martina JA, Diab HI, Lishu L, Jeong AL, Patange S, Raben N, et al. The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci Signal. 2014;7(309):ra9.
19. Huan C, Kelly ML, Steele R, Shapira I, Gottesman SR, Roman CA. Transcription factors TFE3 and TFEB are critical for CD40 ligand expression and thymus-dependent humoral immunity. Nat Immunol. 2006;7(10):1082-91.
20. Martina JA, Diab HI, Li H, Puertollano R. Novel roles for the MiTF/TFE family of transcription factors in organelle biogenesis, nutrient sensing, and energy homeostasis. Cell Mol Life Sci. 2014;71(13):2483-97.
21. Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332(6036):1429-33.
22. Steingrimsson E, Tessarollo L, Reid SW, Jenkins NA, Copeland NG. The bHLH-Zip transcription factor Tfeb is essential for placental vascularization. Development. 1998;125(23):4607-16.
23. Argani P, Aulmann S, Illei PB, Netto GJ, Ro J, Cho HY, et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol. 2010;34(10):1395-406.
24. Antonescu CR, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen CL, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer. 2013;52(8):775-84.
25. Folpe AL, Deyrup AT. Alveolar soft-part sarcoma: a review and update. J Clin Pathol. 2006;59(11):1127-32.
26. Huang W, Goldfischer M, Babayeva S, Mao Y, Volyanskyy K, Dimitrova N, et al. Identification of a novel PARP14-TFE3 gene fusion from 10-year-old FFPE tissue by RNA-seq. Genes Chromosomes Cancer. 2015;54(8):500-5.
27. Malouf GG, Su X, Yao H, Gao J, Xiong L, He Q, et al. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes. Clin Cancer Res. 2014;20(15):4129-40.
28. Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, et al. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat Rev Urol. 2014;11(8):465-75.
29. Argani P. MiT family translocation renal cell carcinoma. Semin Diagn Pathol. 2015;32(2):103-13.
30. Rao Q, Williamson SR, Zhang S, Eble JN, Grignon DJ, Wang M, et al. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol. 2013;37(6):804-15.
31. Green WM, Yonescu R, Morsberger L, Morris K, Netto GJ, Epstein JI, et al. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. Am J Surg Pathol. 2013;37(8):1150-63.
32. Rao Q, Liu B, Cheng L, Zhu Y, Shi QL, Wu B, et al. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol. 2012;36(9):1327-38.
33. Argani P, Yonescu R, Morsberger L, Morris K, Netto GJ, Smith N, et al. Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum. Am J Surg Pathol. 2012;36(10):1516-26.
34. Rao Q, Zhang XM, Tu P, Xia QY, Shen Q, Zhou XJ, et al. Renal cell carcinomas with t(6;11)(p21;q12) presenting with tubulocystic renal cell carcinoma-like features. Int J Clin Exp Pathol. 2013;6(7):1452-7.
35. Camparo P, Vasiliu V, Molinie V, Couturier J, Dykema KJ, Petillo D, et al. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol. 2008;32(5):656-70.
36. Argani P, Hicks J, De Marzo AM, Albadine R, Illei PB, Ladanyi M, et al. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol. 2010;34(9):1295-303.
37. Genega EM, Ghebremichael M, Najarian R, Fu Y, Wang Y, Argani P, et al. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol. 2010;134(6):873-9.
38. Martignoni G, Gobbo S, Camparo P, Brunelli M, Munari E, Segala D, et al. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2011;24(10):1313-9.
39. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003;27(6):750-61.
40. Jeong CW, Cho JS, Lee M, Choi M, Song C, Lee S, et al. Comprehensive genetic characterization of TFE3-positive renal cell carcinoma. Journal of Clinical Oncology. 2018;36(6_suppl):635-.
41. Smith NE, Illei PB, Allaf M, Gonzalez N, Morris K, Hicks J, et al. t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. Am J Surg Pathol. 2014;38(5):604-14.
42. Argani P, Lae M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 2005;29(2):230-40.
43. Altinok G, Kattar MM, Mohamed A, Poulik J, Grignon D, Rabah R. Pediatric renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions and clinicopathologic associations. Pediatr Dev Pathol. 2005;8(2):168-80.
44. Sukov WR, Hodge JC, Lohse CM, Leibovich BC, Thompson RH, Pearce KE, et al. TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients. Am J Surg Pathol. 2012;36(5):663-70.
45. Zhong M, De Angelo P, Osborne L, Paniz-Mondolfi AE, Geller M, Yang Y, et al. Translocation renal cell carcinomas in adults: a single-institution experience. Am J Surg Pathol. 2012;36(5):654-62.
46. Argani P, Olgac S, Tickoo SK, Goldfischer M, Moch H, Chan DY, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007;31(8):1149-60.
47. Klatte T, Streubel B, Wrba F, Remzi M, Krammer B, de Martino M, et al. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. Am J Clin Pathol. 2012;137(5):761-8.
48. Luo X, Luo B, Testa J, Patchefsky A, Dulaimi E. Conflicting Immunohistochemistry and Fluorescence In Situ Hybridization Results on Transcription Factor E3 Translocation Status in Renal Cell Carcinoma: A Case Report. American Journal of Clinical Pathology. 2018;150(suppl_1):S34-S5.
49. Classe M, Gregoire V, Malouf GG, Leroy X. Reply to 'Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas'. Histopathology. 2017;71(5):836-7.
50. Lee HJ, Shin DH, Noh GY, Kim YK, Kim A, Shin N, et al. Combination of immunohistochemistry, FISH and RT-PCR shows high incidence of Xp11 translocation RCC: comparison of three different diagnostic methods. Oncotarget. 2017;8(19):30756-65.
51. Inamura K, Fujiwara M, Togashi Y, Nomura K, Mukai H, Fujii Y, et al. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation. Am J Surg Pathol. 2012;36(1):35-42.
52. Ellis CL, Eble JN, Subhawong AP, Martignoni G, Zhong M, Ladanyi M, et al. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2014;27(6):875-86.
53. Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, et al. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008;112(7):1607-16.
54. Meyer PN, Clark JI, Flanigan RC, Picken MM. Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. Am J Clin Pathol. 2007;128(1):70-9.
55. Rais-Bahrami S, Drabick JJ, De Marzo AM, Hicks J, Ho C, Caroe AE, et al. Xp11 translocation renal cell carcinoma: delayed but massive and lethal metastases of a chemotherapy-associated secondary malignancy. Urology. 2007;70(1):178 e3-6.
56. Dal Cin P, Stas M, Sciot R, De Wever I, Van Damme B, Van den Berghe H. Translocation (X;1) reveals metastasis 31 years after renal cell carcinoma. Cancer Genet Cytogenet. 1998;101(1):58-61.
57. Peckova K, Vanecek T, Martinek P, Spagnolo D, Kuroda N, Brunelli M, et al. Aggressive and nonaggressive translocation t(6;11) renal cell carcinoma: comparative study of 6 cases and review of the literature. Ann Diagn Pathol. 2014;18(6):351-7.
58. Damayanti NP, Budka JA, Khella HWZ, Ferris MW, Ku SY, Kauffman E, et al. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. Clin Cancer Res. 2018.
59. Hou MM, Hsieh JJ, Chang NJ, Huang HY, Wang HM, Chuang CK, et al. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma. Clin Drug Investig. 2010;30(11):799-804.
60. Pwint TP, Macaulay V, Roberts IS, Sullivan M, Protheroe A. An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib. Urol Oncol. 2011;29(6):821-4.
61. Numakura K, Tsuchiya N, Yuasa T, Saito M, Obara T, Tsuruta H, et al. A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib. Int J Clin Oncol. 2011;16(5):577-80.
62. Malouf GG, Camparo P, Oudard S, Schleiermacher G, Theodore C, Rustine A, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol. 2010;21(9):1834-8.
63. Rua Fernandez OR, Escala Cornejo R, Navarro Martin M, Garcia Munoz M, Antunez Plaza P, Garcia Dominguez AR, et al. Renal Cell Carcinoma Associated With Xp11.2 Translocation/TFE3 Gene-fusion: A Long Response to mammalian target of rapamycin (mTOR) Inhibitors. Urology. 2018;117:41-3.
